US Patent

US12343372 — Desmopressin oral compositions

Method of Use · Assigned to Tulex Pharmaceuticals Inc · Expires 2044-04-03 · 18y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of making and using desmopressin oral liquid formulations for treating certain diseases.

USPTO Abstract

Provided herein are desmopressin oral liquid formulations. Also provided herein are methods of making and using desmopressin oral liquid compositions for the treatment of certain diseases including diabetes insipidus, enuresis, hemophilia A, von willebrand disease, high blood urea levels and others.

Drugs covered by this patent

desmopressin-acetate (DESMOPRESSIN ACETATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4432`	—	desmopressin-acetate

Patent Metadata

Patent number: US12343372
Jurisdiction: US
Classification: Method of Use
Expires: 2044-04-03
Drug substance claim: No
Drug product claim: Yes
Assignee: Tulex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.